Hyperfine Inc., based in Guilford, Connecticut, has concluded enrollment in a pivotal contrast-enhanced MRI study, marking a key milestone in its development of the Swoop portable MRI system. The trial, registered under ClinicalTrials.gov as NCT07296263, focuses on assessing the Swoop system’s ability to visualize brain lesions—particularly those associated with blood-brain barrier disruption—using ultra-low-field imaging with gadolinium-based contrast agents. The study targets conditions such as brain tumors and inflammatory disorders, with endpoints centered on lesion appearance across three key metrics.
Hyperfine Enrolls 1,000+ Patients in Contrast MRI Study
Hyperfine Inc. reports completion of enrollment in a multi-center clinical trial evaluating its Swoop portable MRI system with gadolinium-based contrast agents for brain lesion visualization.
SL
Sophie Laurent · FX & Rates Desk · 15 Sept 2026 · 18:55 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
